Ipamorelin

Also referred to as Ipamorelin acetate.

Status: Investigational. Ipamorelin is not an FDA-approved drug product for any indication. It is a growth hormone secretagogue studied mainly in early-stage and preclinical research. The FDA has also made bulk drug substance decisions under sections 503A and 503B of the Food, Drug, and Cosmetic Act that bear on whether and how compounding pharmacies can legally prepare it; these determinations have shifted over time and materially limit legitimate compounding availability. Current status requires verification directly against FDA guidance before any assumption is made about availability.

Ipamorelin is a synthetic peptide studied as a selective growth hormone secretagogue, meaning it is proposed to stimulate growth hormone release without the broader hormonal effects seen with some older secretagogues. It is not an FDA-approved drug product, and its position in the compounding market has been directly shaped by FDA decisions about which bulk drug substances compounding pharmacies may legally use. Those decisions have changed over time, so any statement about current compounding availability needs verification rather than assumption. This page focuses on that regulatory reality alongside what is and is not known from the research.

What it is

Ipamorelin is a pentapeptide belonging to the growth hormone releasing peptide (GHRP) class, sometimes described as a ghrelin mimetic. It is described in the literature as more selective for growth hormone release, with less reported effect on cortisol, prolactin, and appetite hormones compared with some earlier secretagogues in this class, though this selectivity claim originates largely from early and preclinical characterization rather than large confirmatory human trials.

Why people ask about it

Patients researching growth hormone-related peptides frequently encounter ipamorelin discussed alongside CJC-1295 as part of informal combination protocols online. Interest is driven by claims about sleep, recovery, and body composition that circulate in non-clinical sources, well ahead of the underlying evidence and regulatory reality.

Proposed mechanism

Ipamorelin is proposed to act on the ghrelin/growth hormone secretagogue receptor (GHS-R) in the pituitary, stimulating pulsatile growth hormone release in a manner that mimics part of the body's natural signalling. This proposed selectivity for growth hormone release over other hormonal effects is described mainly in preclinical and early pharmacology work, and the degree to which it holds up under sustained real-world use in humans is not established by large controlled trials.

What researchers have studied

Receptor binding and selectivity at the growth hormone secretagogue receptor
Acute growth hormone release patterns following administration in small studies
Comparative signalling profile against other GHRP-class secretagogues
Early exploration of bone and metabolic endpoints in preclinical models
Regulatory characterization under FDA bulk drug substance nomination processes

Human evidence

Published controlled human trials are limited; much of what circulates publicly is small, older pharmacology work rather than robust efficacy trials.
No large, well-controlled human trials establishing benefit for body composition, sleep, or recovery outcomes were identified.
Human safety data over long-term or repeated use has not been systematically established in the published literature.
Claims about selectivity versus other secretagogues rest more on receptor and hormonal marker data than on outcome trials.

Preclinical evidence

Animal studies describing growth hormone release following ipamorelin administration.
Cell-based receptor binding studies characterizing activity at the ghrelin/GHS receptor.
Preclinical models exploring bone density and metabolic markers.

What is not yet known

Whether ipamorelin produces meaningful, durable effects on body composition or recovery in humans is not established.
Long-term safety with repeated use in humans has not been systematically studied.
How current FDA 503A/503B bulk substance determinations apply at any given moment; this changes and must be checked against current guidance rather than assumed from this page.
How compounded ipamorelin products, where they exist, compare to one another in quality and consistency.
Whether the proposed selectivity for growth hormone over other hormones translates into a meaningfully better safety profile in humans compared with related secretagogues.

Regulatory status and access

Because ipamorelin is not FDA-approved and its bulk substance status for compounding has been restricted or reconsidered at points by the FDA, availability through a licensed compounding pharmacy cannot be assumed and depends on current regulatory determinations that this page cannot confirm are current. Compounding, where it exists at all, is never itself an approval. Ask about current availability. Only a physician can determine whether any discussion of ipamorelin is appropriate after an evaluation.

Known and potential risks

Regulatory uncertainty itself is a risk: because bulk substance status has shifted, sourcing outside a verified, currently permitted pathway raises legal and quality concerns.
Unregulated or grey-market sourcing of any growth hormone secretagogue carries product purity, potency, and contamination risks that cannot be verified by the patient.
Effects on other pituitary hormones, while proposed to be minimal, have not been ruled out over long-term use.
Water retention and joint or headache complaints have been informally reported with GHRP-class secretagogues generally.
Any active malignancy is a theoretical concern given growth hormone axis stimulation.
Lack of long-term human safety data means unknown risks cannot be excluded.

Cautions and who may not be a candidate

Active malignancy or unresolved oncologic history.
Pregnancy or breastfeeding.
Undiagnosed symptoms that have not been medically evaluated.
Known pituitary or hypothalamic disorders without specialist input.
Situations where current compounding legality cannot be confirmed.

Questions to discuss with a physician

What is the current FDA bulk drug substance status for ipamorelin, and how does that affect what can legally be discussed or compounded right now?
What does the human evidence actually show, separate from claims circulating online?
What would meaningful monitoring look like if this were ever considered?
How does ipamorelin's evidence base compare with better-studied alternatives for my goals?
What are the specific product-quality risks of sourcing this compound?
Is there a reason to consider this over an FDA-approved option, given the evidence gap?

Frequently asked questions

Is ipamorelin FDA-approved?

No. Ipamorelin is not an FDA-approved drug product for any indication. It remains investigational, and its availability through compounding has also been shaped by separate FDA bulk drug substance decisions.

Can a pharmacy legally compound ipamorelin?

That depends on current FDA determinations about bulk drug substances under sections 503A and 503B, which have changed over time. This page cannot state a permanent answer; current status requires direct verification before any assumption about availability.

Does GOAL.MD sell ipamorelin?

This page is educational content, not an offer of sale. Ask about current availability, and only a physician can determine appropriateness after an evaluation.

What is ipamorelin supposed to do?

It is studied as a growth hormone secretagogue proposed to stimulate pituitary growth hormone release somewhat selectively, but this is based mainly on early pharmacology rather than large confirmatory human trials.

Is ipamorelin the same as CJC-1295?

No. They are distinct peptides sometimes discussed together informally because both relate to growth hormone release, but they act through different receptor pathways and have separate evidence bases.

Why does regulatory status matter so much for this ingredient specifically?

Because FDA bulk drug substance decisions directly determine whether compounding pharmacies may legally prepare ipamorelin at all, its practical availability can change independent of any new clinical evidence, which is unusual compared with many other ingredients discussed here.

Is there strong human evidence for ipamorelin's effects?

No. Human data is limited, and no large controlled trials establishing meaningful clinical benefit were identified in the published literature.

What are the main risks of ipamorelin?

Beyond general growth hormone axis considerations, a major risk is sourcing quality given its unsettled compounding status; product purity and consistency cannot be assured outside a verified, currently legal pathway.

Who should not consider ipamorelin?

People with active malignancy, pregnancy or breastfeeding, undiagnosed symptoms, or known pituitary disorders should not consider it without specialist evaluation, and this should always be framed as a discussion with a physician rather than self-directed use.

This page is educational. Nothing here can be ordered, and nothing here is a prescription or medical advice. Compounded preparations are not FDA-approved. To ask about current availability, visit goal.md/peptides/connect or call or text 314-907-3103.

Medically reviewed by Michael Fitch, MD, MD. Last reviewed 2026-08-13.